1. The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line
- Author
-
Marilena Kampa, Elias Castanas, Anastassia Hatzoglou, Christos Stournaras, Evangelia A. Papakonstanti, and Vassilia-Ismini Alexaki
- Subjects
Male ,Cell signaling ,Ethylketocyclazocine ,Pharmacology ,Biology ,Binding, Competitive ,LNCaP ,Reaction Time ,Tumor Cells, Cultured ,Humans ,Testosterone ,Opioid peptide ,Receptor ,Binding Sites ,Cell growth ,Carcinoma ,Cell Membrane ,Prostatic Neoplasms ,Serum Albumin, Bovine ,Cell Biology ,Prostate-Specific Antigen ,Protein-Tyrosine Kinases ,Actin cytoskeleton ,Cell biology ,Analgesics, Opioid ,Actin Cytoskeleton ,Opioid Peptides ,Receptors, Androgen ,Focal Adhesion Kinase 1 ,Focal Adhesion Protein-Tyrosine Kinases ,Cell Division ,Signal Transduction - Abstract
Neuropeptides influence cancer cell replication and growth. Opioid peptides, and opiergic neurons are found in the prostate gland, and they are proposed to exert a role in tumor regulation, influencing cancer cell growth, as opioid agonists inhibit cell growth in several systems, including the human prostate cancer cell line LNCaP. In the same cell line, the existence of membrane testosterone receptors was recently reported, which increase, in a non-genomic manner, the secretion of PSA, and modify actin cytoskeleton dynamics, through the signaling cascade FAK→PI-3 kinase→Cdc42/Rac1. In the present work, we present data supporting that the general opioid agonist Ethylketocyclazocine (EKC) decreases testosterone-BSA (a non-internalizable testosterone analog) induced PSA secretion. Furthermore, we report that this opioid affects this non-genomic testosterone action, by modifying the distribution of the actin cytoskeleton in the cells, disrupting the above signaling cascade. In addition, after long (>24 h) incubation, opioids decrease the number of membrane testosterone receptors, and reverse their effect on the signaling molecules. In conclusion, our results provide some new insights of a possible action of opioids in prostate cancer control by interfering with the action and the expression of membrane testosterone receptors and signaling.
- Published
- 2004
- Full Text
- View/download PDF